Aprea Therapeutics, Inc. (APRE)
NASDAQ: APRE · Real-Time Price · USD
0.790
+0.000 (0.01%)
At close: Jun 26, 2026, 4:00 PM EDT
0.742
-0.048 (-6.08%)
After-hours: Jun 26, 2026, 5:09 PM EDT
Company Description
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways.
Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications.
The company is headquartered in Doylestown, Pennsylvania.
Aprea Therapeutics, Inc.
| Country | United States |
| Founded | 2006 |
| IPO Date | Oct 3, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 8 |
| CEO | Oren Gilad |
Contact Details
Address: 3805 Old Easton Road Doylestown, Pennsylvania 18902 United States | |
| Phone | 215 948 4119 |
| Website | aprea.com |
Stock Details
| Ticker Symbol | APRE |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $15.00 |
| CIK Code | 0001781983 |
| CUSIP Number | 03836J102 |
| ISIN Number | US03836J2015 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Oren Gilad Ph.D. | Co-Founder, Chief Executive Officer, President and Director |
| John P. Hamill CPA | Senior Vice President, Chief Financial Officer, Principal Accounting Officer and Secretary |
| Dr. Lars B. Abrahmsen Ph.D. | Senior Vice President and Chief Scientific Officer |
| Brian Wiley | Senior Vice President of Corporate Development and Strategy |
| Dr. Michel Afargan Ph.D. | Head of Pharmacology Development |
| Ze'ev Weiss B.Sc., C.P.A. | Chief Business Advisor |
| Dr. Eugene P. Kennedy F.A.C.S., M.D. | Chief Medical Advisor |
| Andrea Epstein | Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 17, 2026 | 8-K | Current Report |
| May 15, 2026 | SCHEDULE 13G | Filing |
| May 15, 2026 | 424B7 | Filing |
| May 13, 2026 | 10-Q | Quarterly Report |
| May 13, 2026 | 8-K | Current Report |
| Apr 30, 2026 | ARS | Filing |
| Apr 30, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 30, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 29, 2026 | EFFECT | Notice of Effectiveness |
| Apr 29, 2026 | 424B3 | Prospectus |